Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial
Cancer Cell · 2024-09 · 42 (9) · 1570-1581.e4
DOI: 10.1016/j.ccell.2024.07.004 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Cell, 2024-09. Verfasst von Wei-Wei Xiao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chemoradiotherapy, DNA Mismatch Repair, Neoadjuvant Therapy. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovent Biologics, AstraZeneca.
Abstract (Originalsprache)
Neoadjuvant chemoradiotherapy (NACRT) was the standard treatment for patients with locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) proteins. In this randomized phase 2 trial (ClinicalTrial.gov: NCT04304209), 134 pMMR LARC patients were randomly (1:1) assigned to receive NACRT or NACRT and the programmed cell death protein 1 (PD-1) antibody sintilimab. As the primary endpoint, the total complete response (CR) rate is 26.9% (18/67, 95% confidence interval [CI] 16.0%-37.8%) and 44.8% (30/67, 95% CI 32.6%-57.0%) in the control and experimental arm, respectively, with significant difference (p = 0.031 for chi-squared test). Response ratio is 1.667 (95% CI 1.035-2.683). Immunohistochemistry shows PD-1 ligand 1 (PD-L1) combined positive score is associated with the synergistic effect. The safety profile is similar between the arms. Adding the PD-1 antibody sintilimab to NACRT significantly increases the CR rate in pMMR LARC, with a manageable safety profile. PD-L1 positivity may help identify patients who might benefit most from the combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; United Laboratory…
- Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
- Department of Radiology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
- Department of Pathology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
- Department of Ultrasound, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
- Innovent Biologics
- AstraZeneca
- CAMS Innovation Fund for Medical Sciences
- Chinese Academy of Meteorological Sciences
- Cancer Research Foundation
Zitieren
APA
Xiao, W. W., Chen, G., Gao, Y. H., Lin, J. Z., Wu, X. J., Luo, H. L., Lu, Z. H., Wang, Q. X., Sun, R., Cai, P. Q., Zhu, C. M., Liu, M., Li, J. B., Wang, Y. R., Jin, Y., Wang, F., Luo, H. T., Li, C. L., Pan, Z. Z., & Xu, R. H. (2024). Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell, 42(9), 1570-1581.e4. https://doi.org/10.1016/j.ccell.2024.07.004
Vancouver
Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell. 2024;42(9):1570-1581.e4. doi:10.1016/j.ccell.2024.07.004
BibTeX
@article{Xiao2024,
author = {Xiao, Wei-Wei and Chen, Gong and Gao, Yuan-Hong and Lin, Jun-Zhong and Wu, Xiao-Jun and Luo, Hui-Long and Lu, Zhen-Hai and Wang, Qiao-Xuan and Sun, Rui and Cai, Pei-Qiang and Zhu, Chong-Mei and Liu, Min and Li, Ji-Bin and Wang, Yi-Rui and Jin, Ying and Wang, Feng and Luo, Hai-Tao and Li, Cai-Ling and Pan, Zhi-Zhong and Xu, Rui-Hua},
title = {Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {9},
pages = {1570--1581.e4},
doi = {10.1016/j.ccell.2024.07.004}
}
EUVIMED